A phase 2 study of ofatumumab in Waldenström’s macroglobulinaemia

BACKGROUND: This study determined the overall response rate (ORR) and safety of ofatumumab monotherapy in patients with untreated and relapsed Waldenström’s macroglobulinaemia (WM). METHODS: Patients (n=37) received up to three cycles of weekly ofatumumab. Cycle 1 (C1) administered ofatumumab 300 mg...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Lancet Haematol
Main Authors: Furman¹, Richard R, Eradat, Herbert A, DiRienzo, Christine G, Hofmeister, Craig C, Hayman, Suzanne R, Leonard, John P, Coleman, Morton, Advani, Ranjana, Chanan-Khan, Asher, Switzky, Julie, Liao, Qiming M, Shah, Damini, Jewell, Roxanne C, Lisby, Steen, Lin, Thomas S
Formato: Artigo
Idioma:Inglês
Publicado: 2016
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5484580/
https://ncbi.nlm.nih.gov/pubmed/27914971
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S2352-3026(16)30166-1
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares